ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "prescribing trends"

  • Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting

    US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

    Ting-Chun Yeh1, Yolaine Jeune-Smith 1, Eli Phillips 1, Ajeet Gajra 1 and Bruce Feinberg 1, 1Cardinal Health Specialty Solutions, Dublin, OH

    Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…
  • Abstract Number: 1917 • 2018 ACR/ARHP Annual Meeting

    Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients

    Yvonne C. Lee1, Bing Lu2, Hongshu Guan3, Jeffrey Greenberg4, Joel Kremer5 and Daniel Solomon6, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Corrona, LLC, Waltham, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6Rheumatology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Experts have implicated physician prescribing rates as a contributing factor to the opioid crisis. However, little is known about heterogeneity in these patterns and…
  • Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting

    Inequity in Biologic DMARD Prescription for Spa across the Globe:  Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study

    Elena Nikiphorou1, Désirée van der Heijde2, Sam Norton3, Robert B.M. Landewé4, Anna Moltó5, Maxime Dougados6, Filip van Den Bosch7 and Sofia Ramiro8, 1LUMC, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Academic Rheumatology, King´s College London, London, United Kingdom, 4Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, 5Paris Descartes University, Paris, France, 6Paris-Descartes University,, Paris, France, 7Rheumatology, Ghent University Hospital, Gent, Belgium, 8Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands

    Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…
  • Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting

    Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis

    Sergio Schwartzman1, Yunfeng Li2, Huanxue Zhou3, Vivian Herrera2 and Jacqueline B. Palmer2, 1Hospital for Special Surgery, New York, NY, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3KMK Consulting Inc, East Hanover, NJ

    Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…
  • Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting

    Variation in the Prescribing Practices of Biologic Dmards

    Heather O. Tory1, Josephine A. Awosogba2, Amish J. Dave2, Jonathan S. Coblyn2, Daniel H. Solomon2 and Sonali P. Desai2, 1Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…
  • Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting

    Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis

    Doquyen H. Huynh1, Carol J. Etzel2,3, Vanessa Cox4, Philip J. Mease5 and Arthur Kavanaugh6, 1Rheumatology, UC San Diego School of Medicine, San Diego, CA, 2PO Box 786, Corrona, LLC., Southborough, MA, 3Department of Epidemiology, UT MD Anderson, Houston, TX, 4CORRONA, Inc, Southborough, MA, 5CORRONA, Seattle, WA, 6UCSD School of Medicine, La Jolla, CA

    Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.